Suppr超能文献

心脏再生:缺血性心力衰竭治疗前沿的新见解

Cardiac Regeneration: New Insights Into the Frontier of Ischemic Heart Failure Therapy.

作者信息

Riching Andrew S, Song Kunhua

机构信息

Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Gates Center for Regenerative Medicine and Stem Cell Biology, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

出版信息

Front Bioeng Biotechnol. 2021 Jan 27;8:637538. doi: 10.3389/fbioe.2020.637538. eCollection 2020.

Abstract

Ischemic heart disease is the leading cause of morbidity and mortality in the world. While pharmacological and surgical interventions developed in the late twentieth century drastically improved patient outcomes, mortality rates over the last two decades have begun to plateau. Following ischemic injury, pathological remodeling leads to cardiomyocyte loss and fibrosis leading to impaired heart function. Cardiomyocyte turnover rate in the adult heart is limited, and no clinical therapies currently exist to regenerate cardiomyocytes lost following ischemic injury. In this review, we summarize the progress of therapeutic strategies including revascularization and cell-based interventions to regenerate the heart: transiently inducing cardiomyocyte proliferation and direct reprogramming of fibroblasts into cardiomyocytes. Moreover, we highlight recent mechanistic insights governing these strategies to promote heart regeneration and identify current challenges in translating these approaches to human patients.

摘要

缺血性心脏病是全球发病和死亡的主要原因。虽然20世纪后期开发的药物和手术干预措施极大地改善了患者的预后,但在过去二十年中死亡率已开始趋于平稳。缺血性损伤后,病理重塑导致心肌细胞丢失和纤维化,进而导致心脏功能受损。成体心脏中心肌细胞的更新率有限,目前尚无临床疗法可使缺血性损伤后丢失的心肌细胞再生。在本综述中,我们总结了包括血管重建和基于细胞的干预措施在内的心脏再生治疗策略的进展:短暂诱导心肌细胞增殖以及将成纤维细胞直接重编程为心肌细胞。此外,我们强调了支配这些策略以促进心脏再生的最新机制见解,并确定了将这些方法转化应用于人类患者时当前面临的挑战。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0e0b/7873479/6a76cc8be7a9/fbioe-08-637538-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验